RT @farma_gregorio: La ESMO crea un marco para medir la capacidad de acción clínica de las dianas moleculares. https://t.co/RZ243ueu7G
RT @farma_gregorio: La ESMO crea un marco para medir la capacidad de acción clínica de las dianas moleculares. https://t.co/RZ243ueu7G
La ESMO crea un marco para medir la capacidad de acción clínica de las dianas moleculares. https://t.co/RZ243ueu7G
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
RT @oncology_bg: This is a good initiative by @myESMO. I praise this work in my latest blog @ecancer https://t.co/cLxbCPHl9Z https://t.co/H…
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
A must read paper @FAndreMD @Annals_Oncology
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
This is a good initiative by @myESMO. I praise this work in my latest blog @ecancer https://t.co/cLxbCPHl9Z
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
Topic of my 1st Journal Club presentation @MDAndersonNews !
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as targets for cancer #precisionmedicine https://t.co/Zr506DO8Lb
Feeling out of touch, how did I just come across the @myESMO #cancer #PrecisionMedicine framework on @GenomeWeb when it's from @CDebyaniPhD @VanAllenLab @rdienstmann @nlbigas? Looking forward to @GA4GH #VICC call today
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
Tools for move ahead in precision medicine field framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) | Annals of Oncology | Oxford Academic https://t.co/IePc
RT @Tincho_Angel: ESCAT alteraciones genéticas para seleccionar pacientes para terapia target. #urooncoIAF #cancer @aaoc @fundacion_FUCA @m…
ESCAT alteraciones genéticas para seleccionar pacientes para terapia target. #urooncoIAF #cancer @aaoc @fundacion_FUCA @myESMO https://t.co/xokGyfWDpq
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actionability of molecular Targets https://t.co/Zr506DO8Lb
Framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) https://t.co/aP0GgjJBGp #Oncology #Cancer #PrecisionMedicine #diagnostics #Pharmaceutical #biotechnology
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @repositiveio: A new publication from @myESMO offers #personalisedmedicine guidance for both physicians and #oncology drug developers on…
RT @repositiveio: A new publication from @myESMO offers #personalisedmedicine guidance for both physicians and #oncology drug developers on…
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) #Genomics #Genetics #Cancer https://t.co/TNM9nILwyx
RT @repositiveio: A new publication from @myESMO offers #personalisedmedicine guidance for both physicians and #oncology drug developers on…
A new publication from @myESMO offers #personalisedmedicine guidance for both physicians and #oncology drug developers on the potential for #cancer patients with specific biomarkers to respond to therapy: https://t.co/NG1Cjpgzd4
RT @ChrisWragg8: Importamt collaborative step towards a common language to desribe actionability of genomic variants in cancer. https://t.c…
RT @ChrisWragg8: Importamt collaborative step towards a common language to desribe actionability of genomic variants in cancer. https://t.c…
RT @ChrisWragg8: Importamt collaborative step towards a common language to desribe actionability of genomic variants in cancer. https://t.c…
#ESMO develops classification system for genomic alterations in tumors #genomics #precisionmedicine #pathology #NGS https://t.co/CWxiYxVqtt
One of an expanding range of systems to standardise somatic variant interpretation. @acgs_news are collaborating with stakeholders from across the cancer community to identify and share good practice and help establish UK guidance.
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) https://t.co/EBAyj03KLH #cancer
framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) https://t.co/dLnzF3PWfG
Importamt collaborative step towards a common language to desribe actionability of genomic variants in cancer. https://t.co/Kt31Cz4d5f
framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) | Annals of Oncology | Oxford Academic https://t.co/Nq1AFDMFZT
RT @YanaMas0614: European Working Group Develops 6-Level System to Classify Tumor Genomic Alterations: https://t.co/sDoVnj3155 #ESMO #preci…
RT @Aiims1742: Very important paper in @Annals_Oncology from @myESMO on developing a tiered scale for clinical actionability for molecular…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
#ESMO develops classification system for genomic alterations in tumors #genomics #pathology #precisionmedicine #NGS https://t.co/EamZP6zzl6
European Working Group Develops 6-Level System to Classify Tumor Genomic Alterations: https://t.co/sDoVnj3155 #ESMO #precisionmedicine #targetedtherapies #biomarkers #genomics #nextgenerationsequencing #cancer #genome #genomics #neoplasms #oncology
RT @weoncologists: The #ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines clinical evidence-based criteria to prio…
RT @weoncologists: The #ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines clinical evidence-based criteria to prio…
RT @weoncologists: The #ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines clinical evidence-based criteria to prio…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @weoncologists: The #ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines clinical evidence-based criteria to prio…
RT @weoncologists: The #ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines clinical evidence-based criteria to prio…
The #ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines clinical evidence-based criteria to prioritise genomic alterations as markers to select patients for targeted #cancer therapies. Great resource from @myESMO @Annals_Oncology ht
#ESMO develops classification system for genomic alterations in tumors #genomics #pathology #NGS #precisionmedicine https://t.co/0RWoSNRk4w
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Aiims1742: Very important paper in @Annals_Oncology from @myESMO on developing a tiered scale for clinical actionability for molecular…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @Aiims1742: Very important paper in @Annals_Oncology from @myESMO on developing a tiered scale for clinical actionability for molecular…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @JAX_CKB: Great new #cancer #genomic framework with a nice mention of @JAX_CKB https://t.co/YMIRnnIkU7
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @DrRobertOConnor: In an age where patients risk being exploited by hyped claims of the value of tumour markers & sequencing, a very welc…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @DrRobertOConnor: In an age where patients risk being exploited by hyped claims of the value of tumour markers & sequencing, a very welc…
In an age where patients risk being exploited by hyped claims of the value of tumour markers & sequencing, a very welcome roadmap emerges from @myESMO https://t.co/KAF8Bihj6c Should aid patients to grade the evidence in support of using personalised
ESMO has published a new framework to rank genomic alterations as targets for cancer precision medicine https://t.co/Uk8tFFsxeq https://t.co/xNVsE7Auiq
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @prat_aleix: will this eventually include RNA-based and protein-based biomarkers as well? or just dna-seq results? thanks and congrats!…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @afarkkila: @myESMO addresses the urgent need to systematicallt interpret molecular targets in #cancer #PrecisionMedicine https://t.co/4…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @NatRevClinOncol: Interesting new article by ESMO outlines a framework to rank genomic alterations as targets for cancer precision medic…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer #precisionmedicine: the @myESMO Scale for Clinical Actio…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…
RT @rdienstmann: ESMO actionalibility scale of cancer variants. First step to harmonized NGS reports. More work on “within-tier” target pri…